Compare IDEXX Laboratories, Inc. (IDXX) vs iShares MSCI India ETF (INDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
IDEXX Laboratories, Inc. vs iShares MSCI India ETF — how do they compare? IDEXX Laboratories, Inc. trades at $518 (market cap $40.43B), while iShares MSCI India ETF trades at $46.03 (market cap $5.73B). The key difference: IDEXX Laboratories, Inc. is far larger — about 7.1× iShares MSCI India ETF's market cap, and IDEXX Laboratories, Inc. is more actively traded (692,164 versus 6,797,522). Which is the better fit depends on your goals — on Pluang, investors hold IDEXX Laboratories, Inc. for 46 Days and iShares MSCI India ETF for 58 Days on average.
| IDXX | INDA | |
|---|---|---|
Market Cap | $40.43B | $5.73B |
Volume | 692,164 | 6,797,522 |
Sector | Health | Broad Market / Factor |
52-Week High | $766.68 | $55.29 |
52-Week Low | $504.70 | $45.42 |
Typical Hold Time | 46 Days | 58 Days |
Enterprise Value | $41.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
IDEXX Laboratories (IDXX) trades at $513.14, up 1.28% with strong fundamentals including 25.03% net income margin and 74.21% ROE. The stock shows bearish technical signals but maintains consistent earnings beats and analyst consensus of $665 price target. Recent acquisition of CoVetAI expands AI capabilities in veterinary workflow intelligence, supporting long-term growth framework.
Outlook remains positive with revenue growth accelerating to $4.3B in 2025 and projected $4.6B in 2026. Key risks include foreign exchange headwinds and weaker U.S. veterinary visits. The 56.5% buy rating from analysts suggests continued confidence in the company's diagnostic innovation pipeline and recurring revenue economics.
INDA trades at $46.03, down 0.2% on the day, with a bearish technical signal driven by moving averages and oscillators. Key financial ratios are unavailable in the provided data, limiting fundamental assessment. Recent news highlights India's economic growth amid sector-specific challenges, including energy security concerns and pharmaceutical export hurdles, which may influence the ETF's underlying holdings.
The outlook remains cautious due to technical weakness and macroeconomic headwinds in India. Opportunities exist if oversold conditions reverse, but risks include regulatory tensions and sector volatility. Investors should await updated financials for a clearer fundamental picture.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About IDEXX Laboratories, Inc.
Idexx Laboratories primarily develops, manufactures, and distributes diagnostic products, equipment, and services for pets and livestock. Its key product lines include single-use canine and feline test kits that veterinarians can employ in the office, benchtop chemistry and hematology analyzers for test-panel analysis on-site, reference lab services, and tests to detect and manage disease in livestock. The firm also offers vet practice management software and consulting services to animal hospitals. Idexx gets about 38% of its revenue from outside the United States.
Read more on IDXX →About iShares MSCI India ETF
INDA tracks the MSCI India Index, providing broad exposure to large and mid-cap companies in the Indian stock market. It is structurally dominated by the financials, information technology, and energy sectors, serving as a core instrument for investors seeking a single-country view of India's long-term economic growth.
Read more on INDA →
